Filing Flows › Industrials › 10x Genomics (TXG)
10x Genomics (TXG) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · 10x Genomics (TXG) Q3 2026 earnings results →
Q3 2026 Revenue up 1% year over year to $151M · 13¢ of every $1 of revenue lost · operating margin -10.7%
10x Genomics made $151M in Q3 2026 (+1% Y/Y): Consumables $134M, Services $9.0M, Instruments $6.9M. Operating margin -10.7%, net loss $19.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $150.7M in Q3 2026, up 1% year over year and roughly flat from the previous quarter. Single Cell was the largest line at 62% of revenue. Spatial added $5.8M year over year (up 16%), 349% of the total change. Spatial declined 57%.
Gross margin was 75.0%, up 7.6 points from Q3 2025. Operating costs exceeded revenue by $16.1M, an operating margin of -10.7%. Operating expenses fell 3% while revenue rose 1%. The quarter ended with a net loss of $19.4M, wider than the previous quarter's $17.9M loss.
Operating cash flow was $15.8M (down 63% year over year). Non-cash charges added back $9.5M of depreciation and amortization and $23.1M of share-based compensation. Working capital and other items added $2.7M. Capital expenditures of $1.0M left free cash flow of $14.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $151M | +1% | -10.7% | −$19.4M | $15.8M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $151M | -13% | -12.9% | −$17.9M | $17.0M |
| Q1 2026 | 10-Q | May 8, 2026 | $151M | -3% | -11.3% | −$13.5M | $26.1M |
| Q4 2025 | 10-K | Feb 13, 2026 | $166M | +0.6% | -11.8% | −$16.3M | $40.8M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $149M | -2% | -21.6% | −$27.5M | $43.2M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $173M | +13% | 17.4% | $34.5M | $17.7M |
| Q1 2025 | 10-Q | May 9, 2025 | $155M | +10% | -25.4% | −$34.4M | $34.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About 10x Genomics
Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience.
In its own words, from its 10-K, filed Feb 13, 2026.
10x Genomics against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +1% against the peers' median +4%. Operating margin: -10.7% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TXG 10x Genomics | Q3 2026 | $151M | +1% | -10.7% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: 10x Genomics 10-Q on SEC EDGAR · CIK 1770787 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns TXG and who is buying
More on TXG
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results